Prospects for the use of biomarkers in the diagnosis of irritable bowel syndrome
https://doi.org/10.31146/1682-8658-ecg-175-3-94-101
Abstract
Irritable bowel syndrome is a chronic functional disorder of the intestine, manifested by altered intestinal habits and recurrent abdominal pain in combination with two or more criteria: association with defecation, association with a change in the frequency of defecation, association with a change in the appearance of the stool. To date, IBS remains a diagnosis of exclusion that needs to be differentiated from a wide range of organic diseases. In recent years, a large number of publications have appeared on the research of etiopathogenesis, diagnosis and treatment of IBS. This literary review highlights the problems of searching for biomarkers of IBS as a way to solve the problem of diagnosis of this pathology and understanding the causes of its occurrence.
About the Authors
V. A. Akhmedov
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Vadim A. Akhmedov, D. Sci. (Med.), Professor, Head of the Department of of Medical Rehabilitation of Postgraduate Education
12 Lenina street, 644043 Omsk
A. K. Sargsyan
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Arthur K. Sargsyan, resident of the department
12 Lenina street, 644043 Omsk
O. V. Gaus
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Olga V. Gaus, Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy, Occupational Diseases
Scopus Author ID: 56598554900
12 Lenina street, 644043 Omsk
References
1. Sheptulin A. A., Vize-Khripunova M. A. Rimskiye kriterii sindroma razdrazhennogo kishechnika IV peresmotra: yest’ li printsipial’nyye izmeneniya? [Roman criteria for irritable bowel syndrome IV revision: are there any fundamental changes?] Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii – Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2016, vol. 26, no. 5, pp. 99–103.
2. Lacy B. E., Patel N. K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med, 2017, vol. 6, no. 11, 99 p. doi: 10.3390/jcm6110099
3. Fominykh YU. A., Uspenskiy YU. P., Zakharenko S. M. Sindrom razdrazhennogo kishechnika i infektsionnyye agenty [Irritable Bowel Syndrome and Infectious Agents]. Dnevnik kazanskoy meditsinskoy shkoly – Diary of the Kazan Medical School, 2016, no. 1 (11), pp. 58–61.
4. Ford A. C., Lacy B. E., Talley N. J. Irritable Bowel Syndrome. The New England journal of medicine, 2017, vol. 376, no. 26, pp. 2566–2578. doi: 10.1056/NEJMra1607547
5. Defrees D. N., Bailey J. Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Primary Care: Clinics in Offi ce Practice, 2017, vol. 44, no 4, pp. 655–671. doi: 10.1016/j.pop.2017.07.009
6. Akhmedov V. A., Orlov I. N., Gaus O. V. Sovremenniye metodi reabilitatcii patcientov s sindromom razdrazhennogo kishechnika [Modern methods of rehabilitation of patients with irritable bowel syndrome]. Terapiya – Therapy, 2017, vol. 3, no. 13, pp. 49–55.
7. Pogromov A. A., Tashchyan O. V., Mnatsakanyan M. G., Dyukova G. M. Spornyye voprosy patogeneza i diagnostiki sindroma razdrazhennogo kishechnika i vospalitel’nykh zabolevaniy kishechnika s SRK-podobnymi simptomami [Controversial issues in the pathogenesis and diagnosis of irritable bowel syndrome and inflammatory bowel diseases with IBS-like symptoms]. Klinicheskaya meditsina – Clinical medicine, 2016, vol. 94, no. 10, pp. 795–800.
8. Camilleri M., Halawi H., Oduyebo I. Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we? Expert Review of Gastroenterology & Hepatology, 2017, vol. 11, no. 4, pp. 303–316. doi: 10.5056/jnm6135
9. Zhao X., Modur V., Carayannopoulos L. N., Laterza O. F. Biomarkers in Pharmaceutical Research. Clinical Chemistry, 2015, vol. 61, no. 11, pp. 1343–1353. doi: 10.1373/clinchem.2014.231712
10. Makker J., Chilimuri S., Bella J. N. Genetic epidemiology of irritable bowel syndrome. World Journal of Gastroenterology, 2015, vol. 21, no. 40, pp. 11353–11361. doi: 10.3748/wjg.v21.i40.11353
11. Guan T., Li T., Cai W. et al. HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis. Oncotarget, 2017, vol. 8, no. 59, pp. 100459–100468. doi: 10.18632/oncotarget
12. Cheung C. K., Wu J. C. Genetic polymorphism in pathogenesis of irritable bowel syndrome. World Journal of Gastroenterology, 2014, vol. 20, no. 47, pp. 17693–17698. doi: 10.3748/wjg.v20.i47.17693
13. Katsumata R., Shiotani A., Murao T. et al. The TPH1 rs211105 gene polymorphism affects abdominal symptoms and quality of life of diarrhea-predominant irritable bowel syndrome. Journal of Clinical Biochemistry and Nutrition, 2018, vol. 62, no. 3, pp. 270–276. doi: 10.3164/jcbn.17–76
14. Jin D. C., Cao H. L., Xu M. Q. et al. Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World Journal of Gastroenterology, 2016. – Vol. 22, № 36. – P. 8137–8148. doi: 10.3748/wjg.v22.i36.8137
15. Zucchelli M., Camilleri M., Andreasson A. N. et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut, 2011, vol. 60, no. 12, pp. 1671–1677. doi: 10.1136/gut.2011.241877
16. Czogalla B., Schmitteckert S., Houghton L. A. et al. A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome. Neurogastroenterol Motil, 2015, vol. 27, no. 5, pp. 717–727. doi: 10.1111/nmo.12548
17. Swan C., Duroudier N. P., Campbell E. et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut, 2013, vol. 62, no. 7, pp. 985–994. doi: 10.1136/gutjnl-2011–301213
18. Wang L., Alammar N., Singh R. et al. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. J Acad Nutr Diet, 2019, no. 19, pp. 2212–2672. doi: 10.1016/j.jand.2019.05.015.
19. Shariati A., Fallah F., Pormohammad A. et al. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J Cell Physiol, 2019, vol. 234, no. 6, pp. 8550–8569. doi: 10.1002/jcp.27828
20. Scallan Walter E. J., Crim S. M., Bruce B. B., Griffin P. M. Postinfectious Irritable Bowel Syndrome After Campylobacter Infection. Am J Gastroenterol, 2019, vol. 114, no. 10, pp. 1649–1656. doi: 10.14309/ajg.0000000000000408
21. Sakhautdinova G. M., Nagayeva R. R., Asanbayeva K. E. Sovremennyye predstavleniya ob etiologii sindroma razdrazhennogo kishechnika [Modern views on the etiology of irritable bowel syndrome]. Meditsinskiy sovet – Medical advice, 2019, no. 3, pp. 152–155.
22. Ghoshal U., Shukla C. R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and Liver, 2017, vol. 11, no. 2, pp. 196–208. doi: 10.5009/gnl16126
23. Chumpitazi B. P., Cope J. L., Holister E. B. et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther, 2015, vol. 42, no. 4, pp. 418–427. doi: 10.1111/apt.13286
24. Wang Z., Xu C. M., Liu Y. X. et al. Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome. Chinese Medical Journal, 2019, vol. 132, no. 8, pp. 889–904. doi: 10.1097/CM9.0000000000000192
25. Zhuang X., Xiong L., Li L. et al. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. J Gastroenterol Hepatol, 2017, vol. 32, no. 1, pp. 28–38. doi: 10.1111/jgh.13471
26. Chong P. P., Chin V. K., Looi C. Y. et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol, 2019, no. 10, 1136 p. doi: 10.3389/fmicb.2019.01136
27. Sundin J., Öhman L., Simrén M. Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. Psychosom Med, 2017, vol. 79, no. 8, pp. 857–867. doi: 10.1097/PSY.0000000000000470
28. Belmonte L., Beutheu Youmba S., Bertiaux-Vandaële N. et al. Role of Toll Like Receptors in Irritable Bowel Syndrome: Diff erential Mucosal Immune Activation According to the Disease Subtype. PLoS ONE, 2012, vol. 7, no. 8, pp. 427–477. doi: 10.1371/journal.pone.0042777
29. Lazaridis N., Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol, 2018, vol. 31, no. 2, pp. 171–187. doi: 10.20524/aog.2018.0229
30. Dlugosz A,. Zakikhany K., Acevedo N., D’Amato M., Lindberg G. Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa from Patients with Irritable Bowel Syndrome. Bio Med Res Int, 2017, no. 2017, 7 p. doi: 10.1155/2017/9624702.
31. Shukla R., Ghoshal U., Ranjan P., Ghoshal U. C. Expression of Toll-like Receptors, Pro-, and Antiinflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis. J Neurogastroenterol Motil, 2018, vol. 24, no. 4, pp. 628–642. doi: 10.5056/jnm18130
32. Shin A., Camilleri M., Vijayvargiya P. et al. Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients with Irritable Bowel Syndrome. Clin Gastroenterol Hepatol, 2013, vol. 11, no. 10, pp. 1270–1275. doi: 10.1016/j.cgh.2013.04.020
33. Bogolyubova A. V., Mayorov A.YU., Mishina Ye. Ye., Shvarts A. M., Belousov P. V. Farnezoidnyy retseptor (FXR) kak potentsial’naya terapevticheskaya mishen’ pri nealkogol’noy zhirovoy bolezni pecheni i assotsiirovannykh zabolevaniyakh [Farnesoid receptor (FXR) as a potential therapeutic target for non-alcoholic fatty liver disease and associated diseases]. Sakharnyy diabet – Diabetes, 2017, vol. 20, no. 6, pp. 449–453.
34. Mosinska P., Szczepaniak A., Fichna J. Bile acids and FXR in functional gastrointestinal disorders. Dig Liver Dis, 2018, vol. 50, no. 8, pp. 795–803. doi: 10.1016/j.dld.2018.05.016
35. Li W. T., Luo Q. Q., Wang B. et al. Bile acids induce visceral hypersensitivity via mucosal mast cell-to-nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis. The FASEB Journal, 2019, vol. 33, no. 2, pp. 2435–2450. doi: 10.1096/fj.201800935RR
36. Ayling R. M., Kok K. Fecal Calprotectin. Adv Clin Chem, 2018, no. 87, pp. 161–190.
37. Kalantari H., Taheri1 A., Yaran M. Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome. Adv Biomed Res, 2015, no. 4, 85 p. doi: 10.4103/2277–9175.156647
38. von Arnim U., Wex T., Ganzert C., Schulz C., Malfertheiner P. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol, 2016, no. 9, pp. 97–103. doi: 10.2147/CEG.S97701
39. Livzan M. A., Lyalyukova E. A., Nechaeva G. I., Osipenko M. F., Dolgikh T. I. Fecal laboratory tests in the complex diagnosis of intestinal diseases. Experimental and clinical gastroenterology. 2015, vol 3, no. 116, pp. 46–48.
40. Sundin J., Stridsberg M., Tap J. et al. Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. Scientifi c Reports, 2018, vol. 8, no. 1, pp. 16821. doi: 10.1038/s41598–018–35241–6
41. Mil’to I.V., Sukhodolo I. V., Gereng Ye.A., Sharardina L. A. Dispersnaya endokrinnaya sistema i kontseptsiya APUD [Dispersed Endocrine System and APUD Concept]. Morfologiya – Morphology, 2011, vol. 139, no. 2, pp. 80–88.
42. El-Salhy M., Lomholt-Beck B., Hauske T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol, 2010, vol. 45, no. 12, pp. 1435–1439. doi: 10.3109/00365521.2010.503965.
43. Ohman L., Stridsberg M., Isaksson S. et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol, 2012, vol. 107, no. 3, pp. 440–447. doi: 10.1038/ajg.2011.458
44. El-Salhy M., Patcharatrakul T., Hatlebakk J. G. et al. Duodenal chromogranin a cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scand J Gastroenterol, 2017, vol. 52, no. 6–7, pp. 691–697. doi: 10.1155/2014/462856
45. Zhang L., Song J., Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil, 2016, vol. 22, no. 2, pp. 181– 192. doi: 10.5056/jnm15137
46. Gieseler F., Ungefroren H., Settmacher U. et al. Proteinaseactivated receptors (PARs) – focus on receptor-receptor-interactions and their hysiological and pathophysiological impact. Cell Communication and Signaling, 2013, no. 11, 86 p. doi: 10.1186/1478–811X-11–86.
47. Du L., Long Y., Kim J. J. et al. Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice. Dig Dis Sci, 2019, vol. 64, no. 3, pp. 729–739. doi: 10.1007/s10620–018–5367-y
48. Jimenez-Vargas N.N., Pattison L. A., Zhao P. et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proc Natl Acad Sci USA, 2018, vol. 115, no. 31, pp. 7438–7447. doi: 10.1073/pnas.1721891115
49. Liang W. J., Zhang G., Luo H. S. et al. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome. Gut and Liver, 2016, vol. 10, no. 3, pp. 382–390.
50. Robles A., Perez Ingles D., Myneedu K. et al. Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis. J Neurogastroenterol Motil, 2019, vol. 31, no. 12, e13718p. doi: 10.1111/nmo.13718
51. Sohn W., Lee O. Y., Lee S. P. et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scand J Gastroenterol, 2014, vol. 49, no. 1, pp. 43–51. doi: 10.3109/00365521.2013.85771
52. Lee H., Park J. H., Park D. I., et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil, 2013, vol. 19, no. 2, pp. 244–250. doi: 10.5056/jnm.2013.19.2.244
Review
For citations:
Akhmedov V.A., Sargsyan A.K., Gaus O.V. Prospects for the use of biomarkers in the diagnosis of irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2020;(3):94-101. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-175-3-94-101
Views:
6703
Email this article 